Nurix Therapeutics

NRIX Lead: Phase 3 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-01-28

Catalyst timeline

GS-6791 Ph1 readout2026GS-6791 Ph1 readout, 2026, notable
zelebrudomide corporate update2026zelebrudomide corporate update, 2026, routine
NX-1607 corporate update2026NX-1607 corporate update, 2026, routine
bexobrutideg Ph3 startMid-2026bexobrutideg Ph3 start, Mid-2026, notable
NX-3911 IND filing2H 2026NX-3911 IND filing, 2H 2026, notable
bexobrutideg (NX-5948) tablet formulation IND2H 2026bexobrutideg (NX-5948) tablet formulation IND, 2H 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (16 active programs)

bexobrutideg

NX-5948 · bexdeg

Small Molecule Target: BTK

Chronic Lymphocytic Leukemia Phase 3 oral Roche
Small Lymphocytic Lymphoma Phase 2 oral Roche
Waldenström's Macroglobulinemia Phase 1 oral Roche
Follicular Lymphoma Phase 1 oral Roche
Marginal Zone Lymphoma Phase 1 oral Roche

zelebrudomide

NX-2127

Small Molecule Target: BTK, IKZF1, IKZF3

Diffuse Large B-Cell Lymphoma Phase 1 oral NCT04830137
Mantle Cell Lymphoma Phase 1 oral
Chronic Lymphocytic Leukemia Phase 1 Phase 1a/1b trial oral
Marginal Zone Lymphoma Phase 1 oral
Waldenström's Macroglobulinemia Phase 1 oral

NX-1607

Small Molecule Target: CBL-B

Undisclosed indication Phase 1 Phase 1a/1b trial oral NCT05107674

NX-0479

GS-6791

Small Molecule Target: IRAK4

Undisclosed indication Phase 1 Gilead

NX-3911

SAR448272

Small Molecule Target: STAT6

Undisclosed indication Phase 1 Sanofi

bexobrutideg

NX-5948

Small Molecule Target: BTK

Multiple Sclerosis Phase 2 oral Roche
Chronic Spontaneous Urticaria Phase 2 oral Roche

pan-mutant BRAF degrader

Small Molecule Target: BRAF

Undisclosed indication Preclinical

Technology platforms

DEL-AI

Fully AI-integrated, DNA-encoded library (DEL)-powered drug discovery engine for targeted protein degradation (TPDs and DACs); disease-agnostic; applied to oncology, inflammation, autoimmunity and other therapeutic areas; leverages 5 billion DEL compounds and machine learning for ligand discovery, degrader design, and optimization.

DAC · Pfizer

Degrader Antibody Conjugate platform combining targeted protein degrader payloads with cell/tissue-selective antibody delivery; designed for oncology and non-oncology; partnered with Pfizer for ADC/DAC development.

DEL-AI · Sanofi

AI-integrated drug discovery platform leveraging E3 ligase expertise to identify targeted protein degraders; focus areas include oncology and autoimmune/inflammatory diseases

Biotech Distilled coverage (6)

2026-08-05 UPDATE: Nurix Therapeutics (NRIX) - The Binary Goes Live 🔒 Paid
2026-07-21 UPDATE: Nurix Therapeutics (NRIX) - HSR Clears, $700M Lands 🔒 Paid
2026-07-09 UPDATE: Nurix Therapeutics (NRIX) - The Re-Rate Delivered 🔒 Paid
2026-06-11 UPDATE: Nurix Therapeutics (NRIX) - The Earlier-Line Read-Through
2026-06-08 UPDATE: Nurix Therapeutics (NRIX) - Roche Validates the Molecular Assassin
2026-04-13 Nurix Therapeutics (NRIX) - Scientific Deep Dive for Bexobrutideg and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.